Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301)

Abstract Background Preoperative chemoradiotherapy (CRT), the current standard of care for locally advanced rectal cancer (LARC), is associated with many radiotherapy (RT)-related side effects. We aimed to evaluate whether S-1 and oxaliplatin (SOX) or folinic acid, 5-FU, and oxaliplatin (mFOLFOX6) c...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Keisuke Miwa, Eiji Oki, Masanobu Enomoto, Keisuke Ihara, Koji Ando, Fumihiko Fujita, Masahiro Tominaga, Shinichiro Mori, Goro Nakayama, Mototsugu Shimokawa, Hiroshi Saeki, Hideo Baba, Masaki Mori, Yoshito Akagi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2021-01-01
coleção:	BMC Cancer
Assuntos:	Rectal cancer Neoadjuvant chemotherapy Chemoradiotherapy SOX mFOLFOX6
Acesso em linha:	https://doi.org/10.1186/s12885-020-07766-5
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!